PReS-FINAL-2070: Efficacy of biologic treatments in juvenile idiopathic arthritis with a polyarticular course: an indirect comparison
نویسندگان
چکیده
Methods Based on a literature review, we identified RCTs of abatacept, adalimumab (ADA), etanercept, infliximab and tocilizumab (TCZ) in pcJIA. Comparative effectiveness was estimated on the reported American College of Rheumatology response rates (JIA ACR30/50/70/90) measured at the end of the randomised, double-blind phase by means of a Bayesian indirect comparison using a fixed-effects ordered probit model. Probabilities of achieving different levels of JIA ACR response were calculated for biologic treatments and placebo using all observed comparisons.
منابع مشابه
PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticularcourse juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH F De Benedetti, N Ruperto, Z Zuber, R Cuttica, R Xavier, I Calvo, N Rubio, E Alekseeva, V Chasnyk, J Chavez, G Horneff, V Opoka-Winiarska, P Quartier, A Spindler, C Keane, K Bharucha, J Wang, D Lovell, A Martini, HI Brunner, PRINTO and PRCSG
متن کاملPReS-FINAL-2064: Effect of Goloimumab a new anti-TNF, in patients with the diagnosis of juvenile idiopathic arthritis
Results 18 patients with the diagnosis of juvenile idiopathic arthritis (15 with juvenile enthesitis associated arthritis, 2 with juvenile psoriatic arthritis and 1 with juvenile idiopathic polyarticular arthritis), for a mean time of 13.7 months per patient (4-26 months). 16 patients have been treated with other biologic agents before. In 13 patients Golimumab was started because of disease pr...
متن کاملJuvenile Idiopathic Arthritis Onset in a Neonate: A Rare Case Report
Background: A common type of chronic arthritis in children and adolescents is juvenile idiopathic arthritis (JIA).According to the International League of Associations for Rheumatology (ILAR) classification, JIA diagnostic criteria include age under 16 years and disease duration of six-weeks. Based on the number of involved joints in the first sixmonths of disease onset, JIA is categorized into...
متن کاملPReS-FINAL-2104: Disease course and predictors of outcome in systemic onset juvenile idiopathic arthritis
Introduction Systemic juvenile idiopathic arthritis (SJIA) is the most common subtype of JIA in Thailand, which represents approximately 33 percents of all JIA patients. The disease course of SJIA and outcome of treatment were varied, depending on multi-factors. In the previous studies, persistent systemic features, younger age at onset, and arthritis of hip are predictors of poor functional ou...
متن کاملPReS-FINAL-2094: Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate
OBJECTIVES To evaluate the benefits of the addition of leflunomide (LEF) in children with polyarticular course juvenile idiopathic arthritis (JIA), non-responsive to standard dose parenteral methotrexate (MTX). METHODS In an observational study, 32 children with polyarticular course JIA failing standard dose MTX (up to 15 mg/m2/week sc for at least 3 and up to 6 months) received additional LE...
متن کامل